哈佛生物科學 HBIO 深 滬
已收盤 09-05 16:00:00 美东时间
0.4782
+0.010
+2.20%
華盛通- 最 高0.4923
- 今 開0.46
- 成交量 35.12万股
- 最 低 0.46
- 昨 收 0.4679
- 總市值 2114.30万
- 52周最高 3.04
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.2813
- 委 比 -88.43%
- 總股本 4421.37万
- 歷史最高 8.75
- 量 比 1.04
- 振 幅 6.90%
- 歷史最低 0.2813
- 每 手 1
- 風險率 0.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harvard Bioscience Offers CFO $100K Retention Bonus
An update from Harvard Bioscience ( ($HBIO) ) is now available. On August 12, 2...
08-14 05:03
Harvard Bioscience Amends Credit Agreement with Lenders
Harvard Bioscience ( ($HBIO) ) has shared an update. On August 8, 2025, Harvard...
08-12 05:05
Harvard Bioscience Enters Sixth Amendment To Credit Agreement; Lenders Agree Not To Test Financial Covenants For Q3 2025; Agrees To Pay $400K Fees To Lenders; Explores Alternative Capital Sources For Refinancing; Says There Is Substantial Doubt About Co's Ability To Continue As A Going Concern
Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") entered into a Sixth Amendment (the "Sixth Amendment") to the Credit Agreement, dated as of December
08-12 04:41
Harvard Bioscience Sees Q3 Sales $19.000M-$21.000M vs $21.75M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.
08-11 19:07
Harvard Bioscience Q2 Adj. EPS $(0.01), Inline, Sales $20.45M Beat $20.40M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $20.45 million which beat the analyst consensus estimate
08-11 19:07
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET
Harvard Bioscience, Inc. will announce its Q2 2025 financial results before the market opens on August 11, 2025, and host a conference call at 8:00 a.m. ET. Participants can register for the call [here](https://www.globenewswire.com/Tracker?data=nfed1QWsvzBQKXOB3N526JmdCUpVVnHg9A2EGOeK2pKjP4KuMspi74Cg2GkHSpZQiE7S4Z0DcMc7YSiwnelA_z8aSGANDmonicvIPUAcbhlqU_B0mG3O49JHRW8DiNX1lCsrS7TPe8SS5QDiL2hy9gMU1mIsRGRseI1I78-ViP0=) to receive dial-in details. Au...
08-04 20:30
Harvard Bioscience announces CEO succession plan
Harvard Bioscience (NASDAQ:HBIO) announced a CEO succession plan under which John Duke will assume the role of president & CEO following the planned retirement of Jim Green, effective July 28, 2025....
07-17 19:34
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
<p><strong>Summary:</strong></p> Harvard Bioscience announced John Duke as its new President & CEO, succeeding Jim Green, who plans to retire after 8 years as Chairman and 6 years as CEO. Duke, currently a Board member and CEO of PMT, brings over two decades of leadership experience. Additionally, Rob Gagnon and Seth Benson have been appointed to the Board of Directors. The company expects Q2 2025 revenue to be $20.4 million, with a gross margin...
07-17 11:00
Harvard Bioscience Faces Nasdaq Compliance Challenge
Harvard Bioscience ( ($HBIO) ) has issued an update. On June 18, 2025, Harvard ...
06-24 05:18
